We believe that this novel PD-L1-containing MUC1-Vax vaccine is an effective and relatively safe therapeutic vaccine against MUC1+ and PD-L1+ tumors, which can get rid of the disadvantages of single checkpoint inhibitor treatments as invalid, since it provokes the body’s stronger anti-tumor immune response, thus controlling and regressing the tumor. The gene discussed is CD274; the disease is neoplasm.